Genetic Variation in 15-Hydroxyprostaglandin Dehydrogenase and Colon Cancer Susceptibility

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Thompson, Cheryl L ^a,b,c   Fink, Stephen P ^b,c   Lutterbaugh, James D ^b   Elston, Robert C ^b,c   Veigl, Martina L ^b,c   Markowitz, Sanford D ^b,c   Li, Li ^a,b,c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE;

15 PGDH GENE; ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; COLON; COLON CANCER; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GERM LINE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; CASE-CONTROL STUDIES; COLONIC NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 84878084472     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064122     Document Type: Article

References (27)

1. Grady WM, Markowitz SD, (2002) Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 3: 101-128.
2. Brown JR, DuBois RN, (2005) COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 23: 2840-2855.
3. Gupta RA, Dubois RN, (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1: 11-21.
4. Markowitz SD, Bertagnolli MM, (2009) Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 361: 2449-2460.
5. Markowitz SD, (2007) Aspirin and colon cancer-targeting prevention? N Engl J Med 356: 2195-2198.
6. Marnett LJ, (1992) Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52: 5575-5589.
7. Wang D, DuBois RN, (2008) Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett 267: 197-203.
8. Rigas B, Goldman IS, Levine L, (1993) Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122: 518-523.
9. Wang D, Wang H, Shi Q, Katkuri S, Walhi W, et al. (2004) Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6: 285-295.
10. Kawamori T, Uchiya N, Sugimura T, Wakabayashi K, (2003) Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 24: 985-990.
11. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, et al. (2001) Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 7: 1048-1051.
12. Tai HH, Ensor CM, Tong M, Zhou H, Yan F, (2002) Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat 68-69: 483-493.
13. Yan M, Rerko RM, Platzer P, Dawson D, Willis J, et al. (2004) 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A 101: 17468-17473.
14. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, et al. (2005) 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 280: 3217-3223.
15. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, et al. (2006) 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A 103: 12098-12102.
16. Yan M, Myung SJ, Fink SP, Lawrence E, Lutterbaugh J, et al. (2009) 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A 106: 9409-9413.
17. Li L, Plummer SJ, Thompson CL, Tucker TC, Casey G, (2008) Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk. Clin Cancer Res 14: 633-637.
18. Davis LG DM, Battey JF (1986) Basic Methods in Molecular Biology. New York: Elsevier.
19. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, et al. (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611-622.
20. Fisher R (1925) Statistical Methods for Research Workers. Edinburgh: Oliver and Boyd.
21. Hochberg Y, Benjamini Y, (1990) More powerful procedures for multiple significance testing. Stat Med 9: 811-818.
22. Tomlinson IP, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, et al. (2008) A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet 40: 623-630.
23. Tenesa A, Farrington SM, Prendergast JG, Porteous ME, Walker M, et al. (2008) Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet 40: 631-637.
24. Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, et al. (2007) A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat Genet 39: 1315-1317.
25. Hoeft B, Linseisen J, Beckmann L, Muller-Decker K, Canzian F, et al. (2010) Polymorphisms in fatty-acid-metabolism-related genes are associated with colorectal cancer risk. Carcinogenesis 31: 466-472.
26. Frank B, Hoeft B, Hoffmeister M, Linseisen J, Breitling LP, et al. (2010) Association of hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD) variants and colorectal cancer risk. Carcinogenesis 32: 190-196.
27. Poole EM, Hsu L, Xiao L, Kulmacz RJ, Carlson CS, et al. (2010) Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev 19: 547-557.